Closing prices for 09 October 2026
Next earnings report: none scheduled in the next five weeks · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Becton, Dickinson and Company trades on NYSE under the ticker BDX. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks BDX has traded between 127.59 $ and 193.07 $. As of 09 October 2026 the price stood 85.77 % of the way from the 52-week low to the high.
Over one year BDX shares rose 20.52 %; over six months they rose 19.15 %. Volatility over 90 days is 27.17 %. Dividends are not included: this is price change only, as of 09 October 2026.
BDX trades at a price-to-earnings ratio of 58.0, above the sector median of 24.8. Price to sales is 3.2, below the sector median of 3.9. Price to book is 2.7, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 181.89 | 183.85 | 181.51 | 183.75 | 1M |
| 08 October 2026 | 179.76 | 182.76 | 178.90 | 182.75 | 2M |
| 07 October 2026 | 180.34 | 182.38 | 177.92 | 180.16 | 2M |
| 06 October 2026 | 183.35 | 187.45 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Becton Dickinson makes syringes, catheters and laboratory equipment — consumables a hospital buys continuously.
The catalogue consists of items consumed in every procedure: needles, intravenous sets, specimen containers. Demand follows procedure volumes and is therefore resilient to the economic cycle — operations are not postponed because of the stock market.
The second part is diagnostic instruments and laboratory automation, running on the instrument-and-consumable model: the analyser is installed in a laboratory and its reagents are bought for years, while changing supplier after method validation is expensive.
The company is simplifying its structure by separating segments and working on manufacturing quality after several product recalls. Risks: device regulation, raw material and logistics costs, and hospital budgets. BDX is a dividend aristocrat.
Address:ONE BECTON DR, FRANKLIN LAKES, NJ, 07417-1880, US
Becton, Dickinson and Company reported revenue of 20.6B $ and net income of 1.1B $ over the last four quarters. Net margin is 5.53 %. Revenue changed by −1.28 % year over year. Market capitalisation is 66.1B $.
BDX has a return on equity of 4.72 %, above the sector median of −41.68 %. Return on assets is 2.24 %, above the sector median of −32.11 %. Operating margin is 10.39 %, above the sector median of −26.84 %.
| 324M |
| MDLNMedline Inc. | 36.26 | +1.45 % | 297M |
| RMDResMed Inc. | 230.43 | +1.63 % | 276M |
| PODDInsulet Corporation | 135.28 | +0.60 % | 244M |
| WSTWest Pharmaceutical Services, Inc. | 368.78 | +1.52 % | 207M |
| 180.12 |
| 180.30 |
| 2M |
| 05 October 2026 | 176.58 | 180.90 | 176.04 | 180.67 | 2M |
| 02 October 2026 | 177.46 | 178.13 | 175.71 | 176.80 | 2M |
| 01 October 2026 | 179.11 | 179.67 | 177.02 | 178.07 | 1M |
| 30 September 2026 | 181.19 | 182.34 | 178.91 | 179.00 | 2M |
| 29 September 2026 | 182.51 | 182.95 | 180.09 | 181.97 | 2M |
| 28 September 2026 | 183.07 | 184.34 | 181.95 | 183.83 | 2M |
| 25 September 2026 | 179.22 | 183.92 | 177.87 | 183.82 | 1M |
| 24 September 2026 | 182.73 | 183.72 | 178.98 | 179.23 | 1M |
| 23 September 2026 | 182.10 | 184.37 | 181.31 | 182.52 | 1M |
| 22 September 2026 | 182.40 | 183.83 | 180.75 | 183.00 | 1M |
| 21 September 2026 | 181.25 | 181.53 | 179.98 | 180.70 | 1M |
| 18 September 2026 | 179.76 | 182.62 | 179.42 | 180.94 | 6M |
| 17 September 2026 | 182.71 | 184.34 | 181.27 | 181.38 | 2M |
| 16 September 2026 | 185.18 | 186.27 | 181.29 | 181.85 | 2M |
| 15 September 2026 | 182.39 | 186.63 | 181.28 | 185.92 | 2M |
| 14 September 2026 | 180.05 | 183.53 | 179.60 | 182.91 | 2M |